The advent of long-acting basal insulin weekly formulations represents a landmark milestone. While ensuring hypoglycemic efficacy and safety, it significantly reduces the injection burden, providing more treatment options for patients with type 2 diabetes (T2DM).At present, icodec insulin, the world’s first insulin weekly formulation, has been included in China’s medical insurance catalogue, and an increasing […]
Tag: T2DM
Banting Science Achievement Award Recipient: Development of Amyloid Inhibitors Promising to Slow T2DM Progression
At the 85th Scientific Sessions of the American Diabetes Association (ADA 2025), the presentation of the Banting Medal for Scientific Achievement was undoubtedly one of the most anticipated highlights. As the highest scientific honor of the ADA, this award commemorates Dr. Frederick Banting—the medical scientist, physician, and Nobel laureate who played a pivotal role in […]
Professor Andreas Liebl (Diabetes and Metabolism Center Bad Heilbrunn, Germany): Reshaping the Future Landscape of T2DM and Obesity Management
Professor Andreas Liebl from the Diabetes and Metabolism Center Bad Heilbrunn, Germany, believes that the iteration and upgrading of innovative drugs will be most critical in the coming years. Drugs targeting GLP‑1, GIP, and glucagon receptors will be continuously optimized and diversified. As I noted earlier, such agents allow us to manage patients from a […]